Medication insights: teprotumumab-trbw (Tepezza) The U.S. Food and Drug Administration (FDA) first approved teprotumumab-trbw (Tepezza) in January 2020 for the treatment of thyroid eye disease...

Insights from Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Studies aim to highlight the impact of various healthcare strategies on patient outcomes and cost containment

Annual conference gathers 2,500+ managed care leaders to discuss complex health care issues.

As assistant vice president of health outcomes, Gleason leads research into healthcare access, costs and outcomes, helping guide benefit strategies for payers and providers

Constant communication across the supply chain limits disruption when a drug is unavailable

Effective: January 2021 Terms of use IF YOU ARE EXPERIENCING A MEDICAL EMERGENCY, DIAL 911 AND/OR SEEK IMMEDIATE ATTENTION FROM A HEALTH CARE PROVIDER. THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE....

Zabrina Watkins Radical welcomeness “At Prime we’re committed to creating an open, inclusive culture that’s purpose-oriented and focused on providing meaningful work for our employees. To do this,...

A strategic deep dive into the latest trend report from Prime Therapeutics reveals how oncology spend is evolving across benefits and what it means for cancer care management

Sept. 27, 2024 - ustekinumab-aauz (Otulfi) Fresenius Kabi has received FDA approval for Otulfi as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is...

Oncology Insights On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to intravenous Imdelltra™ (tarlatamab) for the treatment of adults with relapsed/refractory...

Prime’s Special Investigations Unit is specially trained to protect patients and providers throughout the health care continuum

March 7, 2025 – rivaroxaban 2.5 mg tablet (Xarelto) Lupin launched a generic to Janssen’s Xarelto Factor Xa inhibitor indicated (1) to reduce the risk of major cardiovascular events in patients...

Tennessee In accordance with Texas Senate Bill 1236, Prime Therapeutics provides Texas-based pharmacies with secure online access to their pharmacy benefit network contracts that were executed on...

Heading Example Home Other Navigation Pharmacy + Providers Commercial Formularies Commercial formularies PrimeChoice Accord™ Formulary PrimeChoice Accord™ Formulary Updates NetResults™ A-Series...

Jessica Johnson, clinical consultant at Prime Therapeutics, shares some ways to avoid common fraud schemes

Cover image for FDA Decisions Expected_February 2025 Drug pipeline for February 2025 Prime Therapeutics /fda-decisions-expected-february-2025 About Prime Therapeutics Prime Therapeutics logo Prime...

Event features Pat Gleason, AVP, health outcomes at Prime Therapeutics

Cover image for FDA Decisions Expected: November 2024 Drug pipeline for November 2024 Prime Therapeutics /fda-decisions-expected-november-2024 Prime Therapeutics’ FDA Decisions Expected outlines...

New or expanded indications March 12, 2025 – fluocinolone acetonide intravitreal implant (Iluvien) Alimera; corticosteroid; supplemental NDA (sNDA) approved for consolidation of labeling of...

George Van Antwerp breaks down how Prime is poised to drive affordability in drug pricing

These new solutions reflect Prime's distinctive conflict-free approach to the prescription drug supply chain model.

Prime Therapeutics experts share insights about the classification, cost and impact of these revolutionary drugs

In the latest episode of the “Pharmacy Friends” podcast, learn the latest insights on legislative trends, cutting-edge drug therapies and more from the 22nd annual event

In the latest episode of the “Pharmacy Friends” podcast, experts share how integrating medical and pharmacy benefits can close gaps in care, improve treatment decisions and help manage rising...

This form is specifically used to request a check reissue. For remittance requests, please use the following link: Pharmacy remittance request - Prime Therapeutics LLC. Prime Therapeutics cannot...

Disclaimer THIS WEBSITE IS AN OPTIONAL RESOURCE FOR HEALTH CARE PROVIDERS ONLY. IF YOU ARE NOT A HEALTH CARE PROVIDER OR AUTHORIZED PROFESSIONAL USER, YOU ARE NOT TO USE THIS SITE AT ALL AND ARE...

Upgrade provides streamlined patient support and enhanced digital engagement for data-driven, holistic care

Category Migration Site ID Liferay Token Category Type Old Categories New Read Category Prime Article Type Dry Run - preview only, do not update content Migration UpdateType Migration Output Log

December 2024 December 2023 December 2021 Pharmacy newsletter from Prime Therapeutics that provides information and updates about Prime services. June 2022 Home Other Navigation Pharmacy +...

publications Fall 2024 Prime Therapeutics Report October 21, 2024 Debuting a new name and design, the 41st edition of our managed care report still offers the same in-depth industry articles on...

publications Summer 2024 Prime Therapeutics Report June 11, 2024 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. This issue’s cover story...

July 17, 2026 publications 2026 Medical Pharmacy Trend Report: Part 2 – Drug Overview The 2026 Medical Pharmacy Trend Report: Part 2 – Drug Overview reflects Prime Therapeutics’ long‑standing...

Prime simplifies the cancer care pathway through innovative solutions that help manage complex conditions

Expert Clinical Insights Metastatic Melanoma MEDICATION INSIGHTS: Lifileucel (Amtagvi™) The U.S. Food and Drug Administration (FDA) approved lifileucel (Amtagvi™) in February 2024 through the...

NBC News: Patients weren't asked why they quit taking the weight loss drugs

Washington Post: Doctors and patients struggle with starting and stopping medications with little guidance.

Prime Therapeutics’ analysis of claims data suggests patients require support to ensure continued use and lifestyle modification

Most patients taking drugs such as Wegovy for weight loss discontinue usage within a year, according to Prime Therapeutics

Millions of people desperate to lose weight want to take Wegovy or its sister drug Ozempic

Insurers are using prior authorization and other managed care strategies to control costs associated with the growing number of prescriptions, on- and off-label, for the weight-loss medications

Real-world data show higher treatment persistence among patients using Wegovy compared with older weight-loss medications

Real-world data show many patients discontinue weight-loss medications within the first year

Only around one-third of patients prescribed weight loss drugs such as Novo Nordisk’s blockbuster injection Wegovy continued to take it a year later, according to an analysis shared with CNBC

As more and more high-cost therapies, including cell and gene therapies (CGTs), enter the U.S. market, commercial health plans have multiple tools at their disposal to manage these agents

cover image for 2026 Medical Pharmacy Trend Report: Part 1 - Payer Survey Packed with insights on real-world management trends for the hottest industry topics Prime Therapeutics...

Annual meeting will feature industry research posters and educational sessions

Abby Kim, PharmD, BCOP, is a senior director, clinical strategy and oncology specialty solutions, shares key takeaways from the American Journal of Managed Care (AJMC) forum, “Bridging evidence and...

Annual conference features presentations, panels, discussions and networking

Prerak Parikh represented Prime on a panel at Healthcare Advocate Summit 2025 in Las Vegas on Sept. 4 with other payer/PBM professionals

New indications for approved traditional drugs - 2025 Generic name Brand name Manufacturer Indication(s) Route of administration Month approved* zopapogene imadenovec-drba Papzimeos Precigen...

AAVRh74var adeno-associated virus serotype Rh74var ABSSSI acute bacterial skin and skin structure infections AChR acetylcholine receptor ADHD attention deficit hyperactivity disorder ALK anaplastic...

New indications for approved traditional drugs - 2025 Generic name Brand name Manufacturer Indication(s) Route of administration Month approved* mitomycin intravesical solution Zusduri Urogen...

Jan-Apr 2025 (last posted March 24, 2026): — NADAC Public Report Document #1 — NADAC Public Report Document #2 May-Aug 2025 (last posted January 16, 2026): — NADAC Public Report Document #1 — NADAC...

Generic name Brand name Manufacturer Indication(s) Route of administration Month approved* cosibelimab-ipdl Unloxcyt Checkpoint Metastatic or locally advanced cutaneous squamous cell carcinoma IV...

Generic name Brand name Manufacturer Indication(s) Route of administration Month approved* diazoxide choline Vykat XR Soleno Hyperphagia in Prader-Willi syndrome (≥ 4 years of age) Oral March...

publications Quarterly Drug Approvals: October 2024 This report provides an overview of new drugs and indications approved in 2024 Generic Name Brand Name Manufacturer Indication(s) Month Approved*...

Traditional drug approvals Glossary Traditional drug approvals - 2026 Vaccine and immunization new approvals - 2026 Configure the table properties New indications for approved biosimilars - 2026...

Configure the table properties Cellular and gene therapy and biosimilar approvals Oncology drug approvals - 2026 None Configure the table properties Specialty drug approvals Traditional drug...

Adverse reactions or quality problems experienced with the use of these products may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax....